Reducing pathological crosslinking
to reverse fibrosis

Isterian is developing TG2 inhibitors for inhaled administration to treat IPF

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal respiratory condition characterized by thickening and scarring (fibrosis) of the lungs

Overall, the incidence of IPF is higher in people over 50 years of age, with the median survival being two to three years after diagnosis

There is an urgent need for safe and well-tolerated medicines to halt and reverse disease progression

This is about IPF being correlated with age related diseases

With typical onset occurring between the ages of 50-70, scarring of the lungs becomes worse over time, making it more difficult for the lungs to take in oxygen.

This could be about any drugs on the market or existing tech

The current available treatments make it so that with severe IPF the survival rate of patients (who are predominantly over the age of 50) is 3-5 years.

Isterian's inhibitors are designed to selectively stop TG2 crosslinking

TG2 is a versatile multi-functional protein that aids several important cellular functions including adhesion, proliferation and signaling

Isterian's inhibitors are designed to target the active site of TG2 and selectively stop pathological crosslinking

Learn more about our team

A Cambrian Bio PipeCo

Isterian Biotech is one of the many subsidiaries under the Cambrian Bio umbrella. Cambrian is building the medicines that will redefine healthcare in the 21st century. With a commitment to creating a world where people can be physically and mentally healthy for their entire first century of life, Cambrian is creating therapeutics that combat the diseases of aging by targeting the biological drivers of aging.